Cargando…
BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
The RAS family of proteins is amongst the most highly mutated in human cancers and has so far eluded drug therapy. Currently, much effort is being made to discover mutant RAS inhibitors and in vitro screening for RAS-binding drugs must be followed by cell-based assays. Here, we have developed a robu...
Autores principales: | Bery, Nicolas, Cruz-Migoni, Abimael, Bataille, Carole JR, Quevedo, Camilo E, Tulmin, Hanna, Miller, Ami, Russell, Angela, Phillips, Simon EV, Carr, Stephen B, Rabbitts, Terence H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039175/ https://www.ncbi.nlm.nih.gov/pubmed/29989546 http://dx.doi.org/10.7554/eLife.37122 |
Ejemplares similares
-
Correction: BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
por: Bery, Nicolas, et al.
Publicado: (2018) -
Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds
por: Cruz-Migoni, Abimael, et al.
Publicado: (2019) -
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
por: Quevedo, Camilo E., et al.
Publicado: (2018) -
A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2
por: Bery, Nicolas, et al.
Publicado: (2021) -
Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody
por: Tanaka, Tomoyuki, et al.
Publicado: (2021)